Chronic Paediatric Conditions — MCQs
On this page
A 8-year-old boy experiences sudden episodes where he stops talking mid-sentence, stares blankly for 5-10 seconds with subtle eye fluttering, then immediately resumes normal activity with no post-ictal confusion. Episodes occur 10-15 times daily. EEG shows 3 Hz spike-and-wave discharges during hyperventilation. What is the most appropriate first-line treatment?
A 11-year-old girl with type 1 diabetes for 5 years attends for routine retinal screening. Fundoscopy reveals microaneurysms and occasional dot haemorrhages in both eyes, but no cotton wool spots or new vessels. Visual acuity is normal. Her recent HbA1c is 72 mmol/mol. What stage of diabetic retinopathy is present?
A 5-year-old girl with newly diagnosed focal epilepsy is commenced on carbamazepine. After 10 days, she develops fever, facial swelling, cervical lymphadenopathy, and a widespread maculopapular rash. Blood tests reveal eosinophilia and deranged liver function tests with ALT 450 U/L. What is the most likely diagnosis?
A 13-year-old boy with type 1 diabetes mellitus for 6 years presents for annual review. His growth chart shows progressive deceleration in height velocity over the past 18 months, now below the 2nd centile. His weight is appropriate for height. He reports intermittent abdominal discomfort and occasional loose stools. Blood tests show HbA1c 58 mmol/mol, thyroid function normal. What is the most appropriate initial investigation?
A 7-year-old boy with Dravet syndrome (severe myoclonic epilepsy of infancy) continues to have frequent seizures despite trials of multiple antiepileptic medications. His current medications include sodium valproate and clobazam. Which additional treatment has the strongest evidence base for effectiveness in Dravet syndrome?
A 15-year-old girl with epilepsy presents requesting contraceptive advice. She takes carbamazepine 400mg twice daily for focal epilepsy and has been seizure-free for 18 months. She is in a stable relationship and considering starting the combined oral contraceptive pill. What is the most appropriate advice regarding contraception?
A 8-year-old boy with type 1 diabetes for 2 years develops microalbuminuria on screening. His HbA1c is 72 mmol/mol and blood pressure is on the 95th centile for age. Apart from optimizing glycaemic control, what is the most appropriate next step in management?
A 10-year-old girl with juvenile myoclonic epilepsy (JME) has been seizure-free for 18 months on sodium valproate. Her parents ask about her long-term prognosis and whether she will outgrow her epilepsy. What is the most accurate information to provide?
A 12-year-old boy with type 1 diabetes is admitted with DKA. Initial investigations show pH 7.08, glucose 32 mmol/L, potassium 3.2 mmol/L, sodium 148 mmol/L. He is commenced on 0.9% saline with added potassium and fixed-rate insulin infusion. After 6 hours of treatment, repeat electrolytes show potassium 2.9 mmol/L despite potassium supplementation. What is the most likely explanation for the persistent hypokalaemia?
What is the minimum duration of seizure freedom required before considering withdrawal of antiepileptic medication in a child with epilepsy who has been seizure-free on treatment?
Chronic Paediatric Conditions UK Medical PG Practice Questions and MCQs
Question 131: A 8-year-old boy experiences sudden episodes where he stops talking mid-sentence, stares blankly for 5-10 seconds with subtle eye fluttering, then immediately resumes normal activity with no post-ictal confusion. Episodes occur 10-15 times daily. EEG shows 3 Hz spike-and-wave discharges during hyperventilation. What is the most appropriate first-line treatment?
- A. Sodium valproate (Correct Answer)
- B. Carbamazepine
- C. Levetiracetam
- D. Lamotrigine
- E. Phenytoin
Explanation: ***Sodium valproate*** - This drug is a highly effective first-line treatment for **Childhood Absence Epilepsy (CAE)**, offering coverage if the patient also develops **generalized tonic-clonic seizures**. - The clinical triad of **brief staring spells**, lack of a **post-ictal state**, and **3 Hz spike-and-wave discharges** on EEG confirms the diagnosis and indicates the need for this broad-spectrum anticonvulsant. *Carbamazepine* - This medication is a narrow-spectrum agent primarily used for **focal seizures** and can paradoxically **exacerbate absence seizures**. - Its use is strictly contraindicated when the EEG shows characteristic **generalized 3 Hz spike-waves**. *Levetiracetam* - While it is a broad-spectrum antiepileptic, it is considered a **second-line treatment** for absence seizures due to lower efficacy compared to valproate or ethosuximide. - It is generally preferred for **myoclonic seizures** or as adjunctive therapy rather than primary management for classic CAE. *Lamotrigine* - This is an alternative treatment option but is typically less effective than first-line agents and requires **slow titration** to avoid serious side effects like **Stevens-Johnson syndrome**. - It may be considered if first-line drugs are poorly tolerated, but it is not the initial treatment of choice in a typical pediatric presentation. *Phenytoin* - Similar to carbamazepine, this sodium channel blocker is **ineffective** against absence seizures and may increase the frequency of the episodes. - It is primarily indicated for **status epilepticus** and focal-to-bilateral tonic-clonic seizures, not for primary generalized absence patterns.
Question 132: A 11-year-old girl with type 1 diabetes for 5 years attends for routine retinal screening. Fundoscopy reveals microaneurysms and occasional dot haemorrhages in both eyes, but no cotton wool spots or new vessels. Visual acuity is normal. Her recent HbA1c is 72 mmol/mol. What stage of diabetic retinopathy is present?
- A. No retinopathy
- B. Background (mild non-proliferative) diabetic retinopathy (Correct Answer)
- C. Pre-proliferative diabetic retinopathy
- D. Proliferative diabetic retinopathy
- E. Diabetic maculopathy
Explanation: ***Background (mild non-proliferative) diabetic retinopathy*** - This stage is characterized by the presence of **microaneurysms** and occasional **dot haemorrhages**, which are precisely what is described in the fundoscopy findings. - The patient's long duration of type 1 diabetes (5 years) and suboptimal glycemic control (**HbA1c 72 mmol/mol**) support the development of early diabetic retinopathy. *No retinopathy* - This diagnosis requires a **completely normal fundoscopic examination** with no signs of vascular damage. - The presence of **microaneurysms** and **dot haemorrhages** in this patient explicitly indicates the presence of retinopathy, ruling out this option. *Pre-proliferative diabetic retinopathy* - This stage involves more severe signs of retinal ischemia, such as **cotton wool spots**, **venous beading**, and intraretinal microvascular abnormalities (IRMA). - The question explicitly states there are **no cotton wool spots**, meaning the disease has not progressed to this more advanced stage. *Proliferative diabetic retinopathy* - This is the most severe stage, defined by the presence of **neovascularization** (new blood vessel formation) on the optic disc or elsewhere. - The scenario clearly mentions there are **no new vessels**, thus excluding proliferative diabetic retinopathy. *Diabetic maculopathy* - This condition involves changes in the **macula**, often leading to macular edema or hard exudates that typically impair **central visual acuity**. - This patient has **normal visual acuity**, and there is no specific mention of macular edema or lesions directly affecting the macula's function.
Question 133: A 5-year-old girl with newly diagnosed focal epilepsy is commenced on carbamazepine. After 10 days, she develops fever, facial swelling, cervical lymphadenopathy, and a widespread maculopapular rash. Blood tests reveal eosinophilia and deranged liver function tests with ALT 450 U/L. What is the most likely diagnosis?
- A. Stevens-Johnson syndrome
- B. Drug reaction with eosinophilia and systemic symptoms (DRESS) (Correct Answer)
- C. Acute viral exanthem with coincidental hepatitis
- D. Serum sickness
- E. Kawasaki disease
Explanation: ***Drug reaction with eosinophilia and systemic symptoms (DRESS)***- DRESS syndrome is a severe hypersensitivity reaction characterized by **fever**, **generalized lymphadenopathy**, **facial swelling**, and a **maculopapular rash**, typically occurring 2–8 weeks after starting a drug like **carbamazepine**.- The presence of significant **eosinophilia** and **internal organ involvement** (specifically **hepatitis** with elevated ALT) is a hallmark of this condition compared to other cutaneous drug reactions.*Stevens-Johnson syndrome*- While triggered by **carbamazepine**, SJS is primarily characterized by **mucosal involvement** (e.g., mouth, eyes) and **epidermal necrolysis/skin detachment**, which are absent here.- SJS does not typically present with the prominent **eosinophilia** or significant **lymphadenopathy** seen in DRESS syndrome.*Acute viral exanthem with coincidental hepatitis*- Viral exanthems may cause fever and rash, but they are unlikely to cause the combination of **facial edema** and the severe **ALT elevation (450 U/L)** seen in this patient.- **Blood eosinophilia** is not a feature of most viral infections; it strongly points toward a **hypersensitivity reaction** to the recently introduced medication.*Serum sickness*- Serum sickness is a Type III hypersensitivity reaction causing fever, rash, and **arthralgia**, typically occurring 1–3 weeks after drug exposure (often antibiotics or foreign proteins).- It lacks the characteristic **eosinophilia** and **severe hepatic dysfunction** (hepatitis) that define DRESS syndrome.*Kawasaki disease*- Kawasaki disease presents with prolonged fever and rash, but requires features like **conjunctival injection**, **strawberry tongue**, or **extremity changes** for diagnosis.- It does not typically cause **eosinophilia**, and the temporal relationship with **carbamazepine** initiation makes a drug reaction far more likely.
Question 134: A 13-year-old boy with type 1 diabetes mellitus for 6 years presents for annual review. His growth chart shows progressive deceleration in height velocity over the past 18 months, now below the 2nd centile. His weight is appropriate for height. He reports intermittent abdominal discomfort and occasional loose stools. Blood tests show HbA1c 58 mmol/mol, thyroid function normal. What is the most appropriate initial investigation?
- A. Tissue transglutaminase antibodies (anti-TTG) (Correct Answer)
- B. Short Synacthen test
- C. Insulin-like growth factor 1 (IGF-1) level
- D. Coeliac genetic testing (HLA-DQ2/DQ8)
- E. 72-hour faecal fat collection
Explanation: ***Tissue transglutaminase antibodies (anti-TTG)*** - There is a high association between **Type 1 Diabetes Mellitus (T1DM)** and **Coeliac disease** (shared HLA-DQ2/DQ8), and **anti-TTG IgA** is the first-line screening investigation. - The clinical triad of **growth deceleration**, **abdominal discomfort**, and **loose stools** in a patient with T1DM is highly suspicious for malabsorption due to Coeliac disease. *Short Synacthen test* - This is used to diagnose **Addison is disease** (adrenal insufficiency), which may co-occur with T1DM but usually presents with **hypoglycemia** or hyperpigmentation. - It does not typically explain intermittent loose stools or growth failure while maintaining appropriate weight-for-height. *Insulin-like growth factor 1 (IGF-1) level* - While used to screen for **Growth Hormone deficiency**, it is less likely here as growth failure in GH deficiency often involves **increased subcutaneous fat**. - Primary malabsorption from Coeliac disease is a much more common cause of growth failure in the context of T1DM than isolated pituitary pathology. *Coeliac genetic testing (HLA-DQ2/DQ8)* - These tests have a high **negative predictive value** and are used to rule out Coeliac disease, but they cannot confirm an active diagnosis. - Serological testing with **anti-TTG** is the preferred initial step to detect active autoimmune response to gluten. *72-hour faecal fat collection* - This is an **outdated** and cumbersome method for assessing for **steatorrhea** and does not provide a specific diagnosis. - It has been largely replaced by specific serology and **faecal elastase** for investigating malabsorption or pancreatic insufficiency.
Question 135: A 7-year-old boy with Dravet syndrome (severe myoclonic epilepsy of infancy) continues to have frequent seizures despite trials of multiple antiepileptic medications. His current medications include sodium valproate and clobazam. Which additional treatment has the strongest evidence base for effectiveness in Dravet syndrome?
- A. Ethosuximide
- B. Cannabidiol (CBD) (Correct Answer)
- C. Carbamazepine
- D. Phenytoin
- E. Vigabatrin
Explanation: ***Cannabidiol (CBD)*** - Randomized controlled trials have demonstrated that **adjunctive cannabidiol** significantly reduces seizure frequency in patients with **Dravet syndrome** who are refractory to standard treatments. - It is specifically licensed for use alongside other anti-epileptic drugs like **clobazam** and **valproate** in children two years of age and older. *Ethosuximide* - This medication is the first-line treatment specifically for **absence seizures** and does not have a role in managing the mixed seizure types of Dravet syndrome. - It lacks evidence of effectiveness for the **generalized tonic-clonic** or myoclonic seizures that characterize this developmental encephalopathy. *Carbamazepine* - This drug acts as a **sodium channel blocker**, which is strictly **contraindicated** in Dravet syndrome because it can paradoxically worsen seizures. - Since Dravet syndrome is usually caused by a loss-of-function mutation in the **SCN1A gene** (sodium channel), blocking remaining channels exacerbates the condition. *Phenytoin* - Similar to carbamazepine, phenytoin is a **sodium channel blocker** that should be **avoided** in patients with Dravet syndrome. - Use of this medication can lead to a significant increase in **seizure frequency** and may worsen the patient's clinical status. *Vigabatrin* - This agent is primarily indicated as the first-line treatment for **infantile spasms** (West syndrome) or focal seizures. - It is not an evidence-based treatment for Dravet syndrome and carries a risk of permanent **visual field defects**.
Question 136: A 15-year-old girl with epilepsy presents requesting contraceptive advice. She takes carbamazepine 400mg twice daily for focal epilepsy and has been seizure-free for 18 months. She is in a stable relationship and considering starting the combined oral contraceptive pill. What is the most appropriate advice regarding contraception?
- A. Standard dose combined oral contraceptive pill is safe and effective with carbamazepine
- B. She must stop carbamazepine before starting any hormonal contraception
- C. Switch to levetiracetam first, then start standard contraception after 3 months
- D. Use double dose combined oral contraceptive pill to overcome drug interaction
- E. Carbamazepine reduces effectiveness of combined oral contraceptive; recommend barrier methods, intrauterine device, or depot medroxyprogesterone (Correct Answer)
Explanation: ***Carbamazepine reduces effectiveness of combined oral contraceptive; recommend barrier methods, intrauterine device, or depot medroxyprogesterone***- **Carbamazepine** is a potent **hepatic enzyme inducer**, which increases the metabolism of the **estrogen** and **progestogen** components of the combined oral contraceptive pill (COCP), making it unreliable.- Therefore, non-hormonal methods, **intrauterine devices (IUDs)**, **intrauterine systems (IUSs)**, or **depot medroxyprogesterone acetate** are recommended as they are not affected by hepatic enzyme induction.*Standard dose combined oral contraceptive pill is safe and effective with carbamazepine*- This is incorrect as **carbamazepine** is a strong **enzyme inducer** that accelerates the breakdown of contraceptive hormones.- Using a standard dose COCP with carbamazepine significantly **reduces its efficacy** and increases the risk of an unplanned pregnancy.*She must stop carbamazepine before starting any hormonal contraception*- **Abruptly discontinuing carbamazepine** in a patient with well-controlled epilepsy poses a high risk of **seizure recurrence** or **status epilepticus**.- It is medically inappropriate to stop an effective anti-epileptic drug solely for contraceptive choice when other safe and effective options exist.*Switch to levetiracetam first, then start standard contraception after 3 months*- While **levetiracetam** is not an enzyme inducer, switching a stable patient's anti-epileptic medication solely for contraception is not recommended as it carries risks of **seizure breakthrough** during transition.- Such a change would require careful titration and may delay immediate contraceptive needs, which is not ideal when effective non-oral options are available.*Use double dose combined oral contraceptive pill to overcome drug interaction*- Doubling the dose of the COCP is **not reliably effective** in overcoming the enzyme-inducing effects of carbamazepine and increases the risk of **hormone-related side effects**.- Current guidelines advise against this approach, favoring **long-acting reversible contraceptives (LARCs)** that are not affected by hepatic enzyme induction for patients on enzyme-inducing anti-epileptic drugs.
Question 137: A 8-year-old boy with type 1 diabetes for 2 years develops microalbuminuria on screening. His HbA1c is 72 mmol/mol and blood pressure is on the 95th centile for age. Apart from optimizing glycaemic control, what is the most appropriate next step in management?
- A. Increase blood glucose monitoring frequency to 8 times daily
- B. Start an ACE inhibitor after confirming persistent microalbuminuria on repeat testing (Correct Answer)
- C. Arrange urgent renal biopsy to assess for diabetic nephropathy
- D. Commence statin therapy for cardiovascular protection
- E. Restrict dietary protein to 0.8g/kg/day
Explanation: ***Start an ACE inhibitor after confirming persistent microalbuminuria on repeat testing***- **ACE inhibitors** are the first-line treatment for **diabetic nephropathy** as they provide renoprotection by reducing glomerular capillary pressure and decreasing **microalbuminuria**. They also help manage the elevated **blood pressure**.- It is crucial to confirm **persistent microalbuminuria** (typically 2 out of 3 positive samples over 3-6 months) before initiating ACE inhibitors, as a single measurement can be transiently elevated due to factors like exercise or infection.*Increase blood glucose monitoring frequency to 8 times daily*- While optimizing **glycaemic control** is crucial to slow disease progression, simply increasing monitoring frequency does not directly address the established **microalbuminuria** and **hypertension**. - These complications require active therapeutic intervention with medications in addition to improved glucose management strategies.*Arrange urgent renal biopsy to assess for diabetic nephropathy*- A **renal biopsy** is generally not indicated in children when the clinical presentation (long-standing diabetes, microalbuminuria, hypertension) is highly suggestive of **diabetic nephropathy**.- Biopsy is reserved for atypical presentations, such as rapid decline in renal function, sudden onset **nephrotic syndrome**, or the absence of typical diabetic retinopathy, none of which are present here.*Commence statin therapy for cardiovascular protection*- **Statin therapy** is not the most appropriate immediate next step for an 8-year-old. The primary focus for cardiovascular protection at this age is aggressive control of **blood pressure** and **glycaemia**.- Cardiovascular risk management in pediatric diabetes primarily involves lifestyle modifications and targeted management of **hypertension** and **microalbuminuria** before considering statins.*Restrict dietary protein to 0.8g/kg/day*- Strict **protein restriction** in growing children can negatively impact **growth and development** and is generally not recommended in pediatric diabetic kidney disease.- Current guidelines emphasize pharmacological interventions like **ACE inhibitors** and optimized **glycaemic and blood pressure control** over severe dietary protein restriction.
Question 138: A 10-year-old girl with juvenile myoclonic epilepsy (JME) has been seizure-free for 18 months on sodium valproate. Her parents ask about her long-term prognosis and whether she will outgrow her epilepsy. What is the most accurate information to provide?
- A. JME typically requires lifelong treatment as seizures usually recur if medication is withdrawn (Correct Answer)
- B. Most children with JME can stop medication after 2 years seizure freedom with low recurrence risk
- C. JME spontaneously remits in most cases by age 18 years
- D. Seizure freedom for 18 months indicates cure and medication can be withdrawn
- E. JME will definitely persist into adulthood and treatment withdrawal should never be attempted
Explanation: ***JME typically requires lifelong treatment as seizures usually recur if medication is withdrawn*** - **Juvenile Myoclonic Epilepsy (JME)** is characterized by an extremely high recurrence rate (80-90%) if **antiepileptic drugs** are discontinued, even after long periods of seizure freedom. - While the response to medications like **sodium valproate** is excellent, the condition is a **lifelong genetic generalized epilepsy** that rarely undergoes spontaneous remission. *Most children with JME can stop medication after 2 years seizure freedom with low recurrence risk* - This rule generally applies to several pediatric focal or absence epilepsies, but **JME** is a notable exception due to its **lifelong nature**. - Withdrawing medication in JME patients after only two years carries a very high risk of **relapse**, often presenting as generalized tonic-clonic seizures. *JME spontaneously remits in most cases by age 18 years* - Unlike **childhood absence epilepsy**, JME typically begins in adolescence and persists throughout adulthood. - It does not follow a **self-limiting course**, and patients remain symptomatic or at risk of seizures long after they reach 18 years of age. *Seizure freedom for 18 months indicates cure and medication can be withdrawn* - **Seizure freedom** indicates that the medication is effective at controlling the neural hyperexcitability, not that the underlying **epileptic tendency** is cured. - In JME, 18 months is an insufficient period to consider **treatment withdrawal**, and even then, withdrawal is rarely successful. *JME will definitely persist into adulthood and treatment withdrawal should never be attempted* - While it persists into adulthood, the word "never" is too absolute; some patients may attempt **supervised withdrawal** for specific reasons (e.g., pregnancy planning or side effects). - However, the standard clinical guidance emphasizes that **lifelong therapy** is the norm and most suitable approach for maintaining a seizure-free life.
Question 139: A 12-year-old boy with type 1 diabetes is admitted with DKA. Initial investigations show pH 7.08, glucose 32 mmol/L, potassium 3.2 mmol/L, sodium 148 mmol/L. He is commenced on 0.9% saline with added potassium and fixed-rate insulin infusion. After 6 hours of treatment, repeat electrolytes show potassium 2.9 mmol/L despite potassium supplementation. What is the most likely explanation for the persistent hypokalaemia?
- A. Insulin-driven intracellular shift of potassium compounded by ongoing urinary losses (Correct Answer)
- B. Inadequate initial potassium supplementation rate
- C. Concurrent primary hyperaldosteronism
- D. Laboratory error in potassium measurement
- E. Renal tubular acidosis
Explanation: ***Insulin-driven intracellular shift of potassium compounded by ongoing urinary losses***- In **Diabetic Ketoacidosis (DKA)**, insulin therapy rapidly moves potassium into the intracellular compartment as the **acidosis** resolves, causing a sharp drop in serum levels.- Total body potassium is already depleted due to **osmotic diuresis** and vomiting; starting insulin when potassium is low (initially 3.2 mmol/L) worsens this deficit, compounded by continued urinary losses.*Inadequate initial potassium supplementation rate*- While the replacement rate might require adjustment, it is the underlying **physiological shift** driven by insulin that primarily causes the persistent drop.- Even with appropriate supplementation, the rapid cellular uptake of potassium can transiently lower serum levels, requiring close monitoring and adjustments.*Concurrent primary hyperaldosteronism*- This is a chronic endocrine disorder causing **hypertension** and hypokalemia, which does not fit the acute presentation of **Type 1 Diabetes** and DKA.- There is no clinical evidence provided, such as persistent hypertension or suppressed renin, to support this unrelated diagnosis in an acutely unwell child.*Laboratory error in potassium measurement*- While errors like **hemolysis** can occur, a repeat value of 2.9 mmol/L after 6 hours suggests a consistent downward trend rather than a random lab mistake.- Clinical management should always prioritize the expected **pathophysiological process** (insulin-induced shift) over assuming laboratory error, especially in DKA.*Renal tubular acidosis*- **Renal Tubular Acidosis (RTA)** can cause hypokalemia and metabolic acidosis, but it does not cause the **marked hyperglycemia** seen in this patient.- The context of known **Type 1 Diabetes** and severe hyperglycemia (32 mmol/L) confirms DKA as the primary cause of the electrolyte imbalance, rather than RTA.
Question 140: What is the minimum duration of seizure freedom required before considering withdrawal of antiepileptic medication in a child with epilepsy who has been seizure-free on treatment?
- A. At least 2 years seizure freedom (Correct Answer)
- B. At least 1 year seizure freedom
- C. At least 3 years seizure freedom
- D. At least 6 months seizure freedom
- E. At least 5 years seizure freedom
Explanation: ***At least 2 years seizure freedom*** - According to **NICE guidelines** and standard pediatric neurology practice, antiepileptic drug (AED) withdrawal is generally considered after a child has been seizure-free for a minimum of **2 years**. - This period balances the benefit of stopping medication against the **risk of recurrence**, which is estimated to be approximately **40%** overall. *At least 1 year seizure freedom* - A **1-year** period is considered insufficient for most epilepsy syndromes as the risk of relapse remains significantly high. - Guidelines emphasize a longer duration to ensure **neurological stability** before tapering doses. *At least 3 years seizure freedom* - While some high-risk syndromes may require longer monitoring, **3 years** is not the standard minimum requirement for general pediatric epilepsy. - Delaying withdrawal unnecessarily can increase the risk of **dose-related side effects** and long-term toxicity. *At least 6 months seizure freedom* - A **6-month** interval is far too short and carries an **unacceptable risk** of immediate seizure recurrence. - Most clinical protocols require a more sustained period of **cortical stability** before altering the treatment regimen. *At least 5 years seizure freedom* - Requiring **5 years** of seizure freedom is unnecessarily prolonged for the majority of children. - Extended use of AEDs can lead to **cognitive or behavioral** side effects that could be avoided with a timely trial of withdrawal.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free